Takeda has entered a collaboration to introduce Weave Bio’s AI-native regulatory automation platform across 14 ongoing drug development programmes in various global markets.
WellSpan Health and Johns Hopkins Medicine have renewed their oncology collaboration, aiming to widen patient access to advanced care, clinical expertise, and research initiatives throughout central Pennsylvania, US.
US-based SandboxAQ has introduced AQPotency, a Large Quantitative Model (LQM) designed to virtually screen and predict the potential of drug candidates without the need for a solved protein structure.
Xanadu Quantum Technologies and the University of Alberta in Canada have formed a research partnership focused on advancing algorithms to treat cancer.
Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta (quizartinib), an oral type II FLT3 inhibitor, in China.
Energenesis Biomedical has signed a joint development agreement with Taiwan Tanabe Seiyaku for its investigational topical drug ENERGI-F703DFU to treat diabetic foot ulcers (DFUs).
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.
Evotec and Odyssey Therapeutics have announced a strategic AI-enabled research and development (R&D) partnership to explore new treatments for autoimmune and inflammatory diseases.
Schrödinger has entered a strategic agreement with Bristol Myers Squibb (BMS) to integrate its AI-based co-scientist platform Bunsen into BMS’s research operations.
Phylo has entered a collaboration with Japan-based company Chugai Pharmaceutical to implement Biomni Lab, an agentic AI platform designed for biomedical research, within the latter’s drug discovery operations.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.